Background {#Sec1}
==========

Marfan syndrome (MFS) is a connective tissue disorder with high clinical heterogeneity, mainly involving ocular, skeletal, and cardiovascular systems, with an estimated prevalence of 1:3000--1:5000 \[[@CR1]\]. A large proportion of patients have visible signs, such as tall and slender stature, arachnodactyly, chest deformity, and scoliosis. Most patients have rapidly progressive myopia, and approximately 60% of affected individuals have ectopia lentis. However, cardiovascular abnormality might be the only defect in some MFS patients that is insidious and fatal.

MFS is caused by mutations in the *FBN1* gene, which is located on chromosome 15q21.1 and encodes a 320-kDa extracellular matrix glycoprotein fibrillin-1 \[[@CR2], [@CR3]\], a major component of microfibrils. So far, more than 2500 mutations (HGMD Professional 2018.1 total) have been identified throughout *FBN1*, while missense mutations are the most common type \[[@CR4], [@CR5]\]. Sanger sequencing of *FBN1* and panel sequencing including *FBN1* as well as a number of other genes associated with inherited aortopathies are commonly used to identify mutations \[[@CR6]\]; however, both of these methods have a limitation for detecting *FBN1* large deletions (del) or duplications (dup), which have been reported in up to 7% of MFS patients \[[@CR7]\].

Additionally, Loeys-Dietz syndrome (LDS), another inherited connective tissue disorder, which is caused mostly by *TGFBR1* and *TGFBR2* mutations, is often clinically indistinguishable from MFS \[[@CR8]\]. However, up to now, no large genomic rearrangements in *TGFBR1* or *TGFBR2* have been reported in patients with aortic aneurysm/dissection and LDS features.

In this study, we performed a multiplex ligation-dependent probe amplification (MLPA) testing of *FBN1* and *TGFBR2* in 115 unrelated Marfan or early-onset aortopathy patients that were previously proven to be negative in a panel testing involving 15 genes associated with inherited aortopathy.

Results {#Sec2}
=======

A total of 115 patients with suspected MFS or early-onset aortic aneurysm/dissection, who had a negative result in a 15-gene panel testing, were included in this study and evaluated for gross deletions and duplications in *FBN1* and *TGFBR2* gene by MLPA assay. The baseline clinical characteristics are summarized in Table [1](#Tab1){ref-type="table"}. Of all patients, 19 were classic MFS, which referred to those who met the Ghent criteria independent of genetic results, and 43 were suspected MFS, which referred to those with some positive signs (either aortic dilation or positive family history AND systemic score ≥ 3) but not meeting the criteria yet. Almost half of the patients had no other systemic abnormality except for aortic events. Five novel large deletions encompassing a single exon or multiple exons in the *FBN1* gene were identified in five unrelated patients (Fig. [1](#Fig1){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Patients AD234, AD392, AD533-1, and AD680-1 harbored *FBN1* deletions of exon 43, exon 56, exon 54, and exon 50, respectively, while patient AD437 had a large deletion encompassing exons 44--66 in *FBN1*. These data had been submitted to ClinVar (ClinVar accessions SCV000804313-000804317).Table 1The baseline clinical characteristics of the 115 unrelated patientsCharacteristicsStatistics (*n* = 115) Age (years)29.4 ± 14.9 Male gender87 (75.7%)Primary diagnosis Marfan syndrome19 (16.5%) Suspected Marfan syndrome43 (37.4%) Thoracic aortic aneurysm and dissection53 (46.1%)Values are presented as mean ± SD or *n* (%)Fig. 1Results of semiquantitative MLPA. The results of MLPA for five patients. **a** Reduced relative peak areas of *FBN1* exon 43 for patient AD234. **b** Reduced relative peak areas of *FBN1* exon 56 for patient AD392. **c** Reduced relative peak areas of *FBN1* exon 54 for patient AD533-1. **d** Reduced relative peak areas of *FBN1* exon 50 for patient AD680-1. **e** Reduced relative peak areas of *FBN1* exon 44--66 for patient AD437Table 2Overview of cases with large deletions in *FBN1* genePatient No.Age (y)Deletion breakpointsDeletion (*FBN1* exon affected)PhenotypeAD23424g.48749026-48753819*FBN1*: exon 43Classic MFSAD39238g.48724560-48722281*FBN1*: exon 56Classic MFSAD533-15g.48727672-48726338*FBN1*: exon 54Suspected MFSAD680-114g.48734801-48730690*FBN1*: exon 50Suspected MFSAD43737NA*FBN1*: exon 44--66Classic MFSAll nucleotide positions are represented in relation to the human genome reference sequence (GRCh37/hg19), and position + 1 corresponds to the first nucleotide of the *FBN1* reference sequence (GenBank NC_000015.9) at the genomic DNA (g) level*NA* not available

To detect the breakpoints of deletions, we performed a long-range PCR followed by Sanger sequencing. Finally, the four single-exon deletions were all confirmed, and the breakpoints were found (Fig. [2](#Fig2){ref-type="fig"}). Regrettably, the deletion in AD437 could not be verified by the same method, since the mutated allele did not amplify well. Hence, we performed a quantitative PCR instead. Figure [3](#Fig3){ref-type="fig"} shows that the quantity of genomic DNA from the proband amplified by primer pairs targeting exon 55 and exon 66 was half of that in the control samples, suggesting the true presence of a heterozygous deletion in this region.Fig. 2Sequences of PCR products spanning the breakpoint junctions of the four single exon deletions. **a** \~ 4.8 kb deletion encompassing exon 43 in patient AD234. **b** \~ 2.2 kb deletion encompassing exon 56 in patient AD392. **c** \~ 1.3 kb deletion encompassing exon 54 in patient AD533-1. **d** \~ 4.0 kb deletion encompassing exon 50 in patient AD680-1Fig. 3Verification of gross deletions in AD437 by quantitative PCR. The bar graph shows the relative ratio of DNA from AD437, indicating the presence of a heterozygous deletion in the region

All five *FBN1* large deletion carriers had multiple system deformities. Information on the clinical manifestation of the disease and family history is summarized in Table [3](#Tab3){ref-type="table"}. Three patients (AD234, AD392, and AD437) were classic MFS, while the other two (AD533-1 and AD680-1) both had a systemic score of 6 but did not meet the criteria yet when genetic results were not available, probably due to their young ages. Combined with genetic results, these two patients were eventually diagnosed with MFS. Notably, patient AD437 had a gross deletion involving the last 23 exons, but there was no significant difference in the severity of clinical phenotypes when compared with the other four single-exon deletion carriers.Table 3The information of patients' clinical manifestation and family historyPatientsAD234AD392AD533-1AD680-1AD437Age (y)243851437GenderMaleFemaleMaleMaleFemaleHeight (cm)178167120180177Weight (kg)7058235271Cardiovascular system Aortic diameter (cm)5.63.53.33.24.7 *Z*-score8.82.06.82.16.2 Aortic dissectionYNNNYSkeletal system Pectus carinatum deformityYNAYNY Wrist and thumb signsYYYYY Scoliosis or thoracolumbar kyphosisNNNYN Joint hypermobilityNAYNNN Reduced upper segment/lower segment ratio AND increased arm/heightNNNAYN Hindfoot deformityNAYNNNAOcular Ectopia lentisNYNNNA Myopia/strabismusYYYYNOther features Skin striaeNYNNYFamily historyYNANNY*Y* presence of criterion, *N* absence of criterion, *NA* not available

Discussion {#Sec3}
==========

Marfan syndrome has a highly variable manifestation, from a mild phenotype to early-onset and rapidly progressive MFS. Cardiovascular abnormality could be the only defect in some affected individuals. According to the 2010 revised Ghent criteria, in the absence of family history, the combination of aortic root dilation (*Z* ≥ 2)/dissection and identification of a causal *FBN1* mutation was sufficient to establish a diagnosis of MFS \[[@CR9]\]. Accordingly, we performed an MLPA assay to screen for *FBN1* and *TGFBR2* large genomic rearrangements not only in the diagnosed/suspected MFS patients but also in those early-onset aneurysm/dissection patients with minor skeletal and ocular involvement, who had a negative result in a 15-gene panel testing associated with heritable aortopathy.

Finally, five patients with large *FBN1* deletions were identified in our cohort. All five patients had multiple systemic deformities, and three of them met the 2010 Ghent criteria when genetic results were not available, while the other two met the diagnostic criteria until *FBN1* gross deletions were detected, probably due to their young ages. Meanwhile, no gross deletions/duplications were identified in patients with only aortic aneurysm/dissection but without other systemic involvement. This result supported the hypothesis that *FBN1* gross deletions usually lead to classic MFS \[[@CR10]--[@CR12]\].

Although gross genomic rearrangement within the *FBN1* gene only contributed to a small proportion of MFS genetic causes (1.8--2.9%) (UMD, <http://www.umd.be/FBN1/>; HGMD, <http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FBN1>), it was important to identify the pathogenic mutation to afford the patient an opportunity for prenatal testing and preimplantation genetic diagnosis (PGD). *FBN1* mutations could be identified by sequencing in most Marfan patients (up to 93% in classic Marfan patients) \[[@CR13]\]. However, Sanger sequencing and next-generation sequencing are commonly used in clinical genetic testing and are limited in their ability to detect large deletions and duplications. MLPA is a commonly used method to screen large del/dup, commercially, easily, and rapidly. In our cohort, 5 out of 62 patients (8.1%) with diagnosed or suspected MFS but with negative results in panel sequencing had large *FBN1* deletions, which proved it to be efficacious and cost-effective to screen for *FBN1* large genomic rearrangement in those MFS patients with multiple systemic involvements and a negative *FBN1* sequencing result.

Since MLPA and SNP (single-nucleotide polymorphism) arrays are more applicable in clinical genetic testing, increasing gross *FBN1* genomic deletions/duplications has been reported (summarized in Table [4](#Tab4){ref-type="table"}), but until now, there has been no definite and conclusive genotype-phenotype correlation. Current studies reveal that the whole gene deletion of *FBN1* did not lead to a more severe phenotype \[[@CR12]\], and in-frame deletion involving exon 24--53 seemed to result in a high risk of early-onset and rapidly progressive form of MFS \[[@CR11], [@CR14]--[@CR16]\].Table 4Overview of MFS cases with gross deletions in *FBN1* geneVariationPatientReference PMID (year)Deletion (*FBN1* exon affected)Affected domainsAge (y)Phenotype in papersSingle-exon deletion *FBN1*:g.46,701,985_46,728,871 (Ex1)--25Classic MFS17492313 (2002) *FBN1*:Ex1--NAClassic MFS24501682 (2013) *FBN1*:Ex1--NAClassic MFS24793577 (2014) *FBN1*:Ex2--52Classic MFS11700157 (2001) *FBN1*:Ex31st EGF-likeNAMFS21907952 (2011) *FBN1*:Ex63rd EGF-like49Potential MFS28842177 (2017) *FBN1*:c.3603_3668 del (Ex29)18th cbEGF-likeAfter birthNeonatal MFS10441700 (1999) *FBN1*:Ex3019--20th cbEGF-like\< 1Suspected Beals-Hecht syndrome25944730 (2015) *FBN1*:Ex3221--22th cbEGF-like1Neonatal MFS18412115 (2008) *FBN1*:Ex3625--26th cbEGF-likeNAClassic MFS19839986 (2009) *FBN1:*g.48,749,026_48,753,819 del (Ex43)7th TB, 29th cbEGF-like24Classic MFSIn this study *FBN1*:g.48,734,801-48,730,690 del (Ex50)35th cbEGF-like14MFSIn this study *FBN1*:Ex528th TB, 36th cbEGF-like40Classic MFS11700157 (2001) *FBN1*:g.48,727,672-48,726,338 del (Ex54)37--38th cbEGF-like5MFSIn this study *FBN1:*g.48,724,560_48,722,281 del (Ex56)39--40th cbEGF-like38Classic MFSIn this studyMulti-exon deletion *FBN1*:Ex1--51--3rd EGF-like27Classic MFS21936929 (2011) *FBN1*:g.46,580,456_46,883,035 (Ex1-16)1--3rd EGF-like, 1st TB, 4--10th cbEGF-like40Classic MFS17492313 (2002) *FBN1*:Ex1--361--3rd EGF-like, 4--26th cbEGF-like, 1--5th TB15Classic MFS28842177 (2017) *FBN1*:g.48,890,962_48,922,918 (Ex2-4)1--2nd EGF-like32Classic MFS29850152 (2018) *FBN1*:Ex6--653rd EGF-like, 4--47th cbEGF-like, 1--9th TBNAClassic MFS24793577 (2014) *FBN1*:Ex13--497--34th cbEGF-like, 3--7th TB5MFS18412115 (2008) *FBN1*:Ex24--2614--16th cbEGF-likeAfter birthNeonatal MFS20455198 (2010) *FBN1*:Ex33--3821--26th cbEGF-like, 6th TB1Neonatal MFS24199744 (2014) *FBN1*:Ex34--4323--29th cbEGF-like, 6--7th TB22Classic MFS19863550 (2010) *FBN1*:Ex37--6526--47th cbEGF-like, 3--9th TBNAClassic MFS24793577 (2014) *FBN1*:Ex42--437th TB, 29th cbEGF-like\> 46Classic MFS11710961 (2001) *FBN1*:Ex44--4629--31th cbEGF-like\> 6Childhood onset MFS11710961 (2001) *FBN1*:Ex44--6629--47th cbEGF-like, 8--9th TB37Classic MFSIn this study *FBN1*:Ex48--5333--37th cbEGF-like, 8th TB15Neonatal MFS28842177 (2017) *FBN1*:Ex49--5034--35th cbEGF-like3Neonatal MFS28842177 (2017) *FBN1*:Ex50--6335--46th cbEGF-like, 8--9th TB65MFS19659760 (2009) *FBN1*:Ex58--6341--46th cbEGF-like17Juvenile onset classic MFS17189636 (2007) *FBN1*:c.7456_7821 del^\*^ (Ex61--64)43--46th cbEGF-like48Classic MFS1631074 (1994)Whole gene deletion *FBN1*:Ex1--66Full gene16Incomplete MFS20478419 (2010) *FBN1*:Ex1--66Full gene42Classic MFS21936929 (2011) *FBN1*:Ex1--66Full gene15Classic MFS21936929 (2011) *FBN1*:Ex1--66Full gene12Classic MFS21936929 (2011) *FBN1*:Ex1--66Full gene41MFS21063442 (2011) *FBN1*:Ex1--66Full gene39MFS21063442 (2011) *FBN1*:Ex1--66Full gene16MFS21063442 (2011) *FBN1*:Ex1--66Full gene13MFS21063442 (2011) *FBN1*:Ex1--66Full gene27MFS21063442 (2011) *FBN1*:Ex1--66Full gene21MFS21063442 (2011) *FBN1*:Ex1--66Full gene34MFS21063442 (2011) *FBN1*:Ex1--66Full gene5Potential MFS21063442 (2011) *FBN1*:Ex1--66Full gene13Potential MFS21063442 (2011) *FBN1*:Ex1--66Full gene8Potential MFS21063442 (2011) *FBN1*:Ex1--66Full gene13Classic MFS22260333 (2012) *FBN1*:g.48,931,968_51,102,375 (Ex1--66)Full gene14MFS27615407 (2016)*NA* not available\*The deletion was represented as nt. 4762_5127 in partial cloned sequence of *FBN1* (PMID:1852207), and it was converted into its standardized nomenclature in accordance with HGVS (Human Genome Variation Society), in which the position + 1 corresponds to the A of the ATG start codon of the mRNA reference sequence (GenBank NM_000138) at the cDNA (c) level. Except for this, all of the other nucleotide positions and patient phenotypes were shown as it was reported in the reference article

Conclusions {#Sec4}
===========

In summary, our data expand the number of large *FBN1* deletions and emphasize that screening for gross deletions in *FBN1* genes is necessary for clinically suspected MFS patients, especially in those who have a negative result in conventional sequencing methods.

Methods {#Sec5}
=======

Participants {#Sec6}
------------

Patients with MFS or early-onset aortopathy were referred for a genetic test from the Center of Vascular Surgery in Fuwai Hospital and Department of Cardiovascular Surgery in Xiangya Hospital Central South University. Of these, 115 patients in whom no causal mutation was identified in a 15-gene panel associated with heritable aortopathy, including *ACTA2*, *CLO3A1*, *FBN1*, *FBN2*, *MYH11*, *MYLK*, *NOTCH1*, *PRKG1*, *SKI*, *SLC2A10*, *SMAD3*, *SMAD4*, *TGFB2*, *TGFBR1*, and *TGFBR2*, were enrolled in this study to screen for *FBN1* and *TGFBR2* large del/dup.

Multiplex ligation-dependent probe amplification (MLPA) {#Sec7}
-------------------------------------------------------

MLPA assays were performed to detect *FBN1* and *TGFBR2* large deletions or duplications using the commercially available SALSA MLPA kits P065 and P066 (MRC-Holland, Amsterdam, The Netherlands), which contained probes for all exons of *FBN1* and *TGFBR2*. According to the manufacturer's instructions, a total of 100--200 ng of genomic DNA of each patient was used for hybridization, and amplification products from each MLPA assay were separated by capillary electrophoresis on an ABI 3500XL Dx Genetic Analyzer (Life Technologies, USA). The results were analyzed using Coffalyser software. Deletions and duplications with deviations more than 30% were suspected as significant alterations.

Sanger sequencing {#Sec8}
-----------------

To verify the results of MLPA and identify the breakpoints of the deletions, we performed a long-range PCR and subsequent Sanger sequencing. Primers flanking the predicted deletions were designed and LA Taq Hot Start Version kit (Takara, Japan) was used in the PCR system with the following cycling process: 5-min initial denaturation at 96 °C, 30 cycles of 10 s at 98 °C, and 15 min at 68 °C, finished by a 10-min final extension step at 72 °C. Then, the products were detected through agarose gel electrophoresis and sequenced by the inner primers on the ABI 3730XL Genetic Analyzer.

Quantitative PCR {#Sec9}
----------------

Quantitative PCR (qPCR) with the SYBR green reporter dye was performed to quantify relative target gene regions copy number in genomic DNA, and housekeeping gene *GAPDH* (glyceraldehyde 3-phosphate dehydrogenase) was used as the reference gene. The primer pairs were designed by Primer3 Input (<http://bioinfo.ut.ee/primer3-0.4.0/>) (see Additional file [1](#MOESM1){ref-type="media"}). All qPCRs were performed using 2 × SYBR FAST qPCR Kit Master Mix (KAPA Biosystems, America) with the QuantStudio 6 Flex Real-Time PCR System.

Additional file
===============

 {#Sec10}

Additional file 1:**Table S1.** The quantitative PCR primer pairs for AD437. (PDF 132 kb)
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